The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Join the Hive!

Featured Stings

Matthias in Canada

Worldwide consumer confidence has shot up to its highest level for four years according to a survey of 130 Global Retail leaders

What can stop the ‘too big to fail’ bankers from terrorising the world?

Intergenerational, intercultural, interactive – The 2015 edition of JADE’s Generations Club: Transforming Europe into an entrepreneurial society

EU Commission expects consumer spending to unlock growth

MWC 2016 LIVE: Industry looks to reduce mobile gender gap

The EU risks trade relations with China over the Tata hype about steel

EU Parliament shows its teeth in view of 2014 elections

Investing in working conditions and quality jobs

EU Parliament and Council: Close to agreement on the bank resolution mechanism

Currency Union might not let an independent Scotland join the EU as the “Yes” front now leads

Eurozone: Black economy loves the South

Digital business is Europe’s best hope to get back to growth

Ukraine: turning challenges into opportunities


Berlin wants to break South’s politico-economic standing

After swallowing effortlessly the right to be forgotten time for Google Ads now to behave

A new way to teach active citizenship to students?

Sponsored content: when QUALITY meets OPEX in manufacturing

The US and EU decisively oppose Erdogan’s plans for Turkey and beyond

Brexit uncertainty keeps shaking the world’s financial markets

New skills needed for medical students in Industry 4.0

Commission: New proposal for centrally managed bank resolution

An American duel in Brussels: Salesforce against Microsoft over Linkedin deal

Is there a cure for corruption in Greece?

“Airbnb and YouTube are two great examples of a crowd based capitalism”, key stakeholders outline the boundaries of the 4th Industrial Revolution in Davos

TTIP fight round 6: last chance for the negotiators to finally open up as they touch the Brussels ring

Is Eurozone heading towards a long stagnation?

German opposition win in Lower Saxony felt all over Europe

Cyprus tragedy reveals Eurozone’s arbitrary functioning

The European Sting at the Retail Forum for Sustainability live from Barcelona

A new world that demands new doctors in the fourth industrial revolution

The consequences of Brexit seen by a European young entrepreneur

World Retail Congress Dubai 2016: Retail’s night of nights

Why Obama asks approval from Congress to bomb Syria?

Merkel had it her way with the refugees & immigrants but can Greece and Turkey deliver?

It’s not summer holidays what lead to the bad August of the German economy

The EU Commission is lying to the “Right2Water” campaign

The ECB accuses the politicians of inaction, continues injecting billions to banks

China, forever new adventures

Everybody against Germany over the expensive euro

For the future of Europe youth remains a priority

The US bugged Europe: Is this news?

The Commission accused of tolerating corruption and fraud in taxation

Turkey caught in a vicious Syrian circle bringing terror and war at home

ECB asks for more subsidies to banks

Can the EU last long if it cuts Cyprus out?

EU tourism industry expects a new record year in 2014

Could entrepreneurship be the real cure against the side effects of Brexit?

The EU Parliament blasts the Council about the tax dealings of the wealthy

EU plans to exploit the Mediterranean Sea and the wealth beneath it

Ukraine turns again to the EU for more money

European Youth Forum welcomes adoption of Sustainable Development Goals and calls on European countries to not ignore them!

EU officially launches its first naval mission against migrant smugglers

The EU slowly exits from “Excessive Deficit Procedure” and hopefully from ‘Excessive Austerity Procedure’ too

Eurozone: Inflation plunge to 0.4% in July may trigger cataclysmic developments

EU prepares a banking union amidst financial ruins

EU-US resume trade negotiations under the spell of NSA surveillance

Where is heading Putin’s Russia?

Benjamin Franklin was wrong: Amazon can tax evade

Eurozone recession subsides

More Stings?

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s